RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The firm engages in the development and licensing of its portfolio of medicinal products candidates. Its products include aviptadil, for respiratory indications such as sarcoidosis and pulmonary hypertension; and atexakin alfa, for the treatment of diabetic neuropathy. The company was founded in 2013 and is headquartered in Geneva, Switzerland.